[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100277507":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":46,"collaborators":18,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nīmes","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JET ECHO","EXPERIMENTAL","Transmitral flow estimation",[13],"Procedure: Transmitral flow estimation",{"label":15,"type":16,"description":17,"interventionNames":18},"NO JET ECHO","NO_INTERVENTION","no bedside echocardiography",null,[20],{"type":21,"name":11,"description":22,"armGroupLabels":23,"otherNames":18},"PROCEDURE","Estimation of the transmitral flow of the inferior vena cava and its variations",[9],[25,37],{"facility":26,"status":18,"city":27,"state":18,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":18},"CHU Arnaud de Villeneuve","Montpellier","34295","France","FR",{"type":32,"coordinates":33},"Point",[34,35],3.87635,43.61093,{"lat":35,"lon":34},{"facility":38,"status":18,"city":39,"state":18,"zip":40,"country":29,"countryCode":30,"cosmosGeoPoint":41,"geoPoint":45,"contacts":18},"CHU Nimes","Nîmes","30029",{"type":32,"coordinates":42},[43,44],4.35788,43.83665,{"lat":44,"lon":43},{"type":47,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100277507","management-of-acute-heart-failure-contribution-of-ultrasound-daily-in-bed-patient-adjustment-on-therapy-with-impact-measure-on-re-hospital-rate-during-30-days-100277507",false,"NCT02892227","Management of Acute Heart Failure: Contribution of Ultrasound Daily \"in Bed Patient\" Adjustment on Therapy With Impact Measure on re Hospital Rate During 30 Days","MANAGEMENT OF ACUTE HEART FAILURE: THE CONTRIBUTION OF DAILY 'BEDSIDE' ULTRASOUND TO THERAPEUTIC ADJUSTMENTS, WITH MEASURED IMPACT ON 30-DAY RE-HOSPITALISATION RATES","JECICA","Inclusion Criteria:\n\nThe patient or his representative must be given free and informed consent and signed consent.\n\n* The patient must be affiliated or beneficiary of a health insurance plan.\n* The patient is available for a follow-up 6 months.\n* The patient is of age or older (\\>) 18.\n* Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV.\n* Patient with impaired LVEF \\\u003C50%.\n* Patient with Nt-proBNP values\\> 1200pg \u002F ml.\n\nExclusion Criteria:\n\n* The subject takes part in another study.\n\n  * The subject is exclusion period determined by a previous study.\n  * The subject is under judicial protection.\n  * The subject or his representative refuses to sign the consent.\n  * It is not possible to give the subject or his representative informed information.\n\nNon-inclusion criteria for those diseases or conditions associated (s) interfere (s):\n\n* The patient is pregnant or is breastfeeding.\n* The patient is already included in a surveillance program (PRADO, OSICAT).\n* Patient with a mechanical or biological mitral prosthesis.\n* History of mitral stenosis.\n* severe valvular surgery with maturity in months (\\\u003C30 days).\n* chronic renal impairment on dialysis.\n* High grade AV block (AVB and BAV3 2\u002F1).\n* Hypertrophic cardiomyopathy.\n* Cardiogenic shock.\n* Contraindications to furosemide.","ALL","18 Years","90 Years",{"count":60,"type":61},250,"ACTUAL","INTERVENTIONAL",[64],"NA","Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more suitable.\n\nThis therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30 days and mortality, less alteration of biological parameters myocardial, kidney and liver.",[67],"Heart Failure",[69],"bedside echography","COMPLETED","2026-03-11",{"date":73,"type":61},"2026-03-12",{"date":75,"type":61},"2016-11-15",{"date":77,"type":61},"2019-06-05",{"name":5,"class":6},2]